Seroprevelence Of Hepatitis E Virus In Human in Najran

by

Mahmoud Alfifi

Applied medical science department

Community college, Najran university

الانتشار المصلى لفيروس التهاب الكبد هاء في الإنسان في نجران

محمود الفيفي

قسم العلوم الطبية-تقنية المختبرات

كلية المجتمع- جامعة نجران

Abstract:

The seroprevalence of hepatitis E virus (HEV) infection in Najran, a rural community's province in the southwestern of Saudi Arabia was investigated. Blood samples from 1080 person (360 hepatic patients and 720 apparently healthy volunteers) were collected from October 2011 to March 2012. Serum samples were tested for anti-HEV IgG antibodies by enzyme linked immunosorbent assay (ELISA) method. Anti-HEV IgG antibodies were detected in a total of 88 cases out of 360 hepatic samples with a percentage of 25%. None of the apparently healthy volunteers were positive for HEV antibodies.

الملخص:

تم دراسة الانتشار المصلي لعدوى فيروس الالتهاب الكبدى E (HEV) في نجران، فى المجتمع الريفي في جنوب غرب المملكة العربية السعودية. تم تجميع عينات الدم من ١٠٨٠ شخص (مرضى الكبد ٣٦٠ و ٧٢٠ من المتطوعين الأصحاء) خلال الفترة من أكتوبر ٢٠١١ إلى مارس ٢٠١٢. تم اختبار عينات مصل الدم للكشف عن الأجسام المضادة IgG لفيروس الـ HEV باختبار الاليزا (ELISA). ، وقد أظهرت نتائج هذا الاختبار وجود الأجسام المضادة IgG لفيروس الـ HEV في ٨٨ عينة من مجموع ٣٦٠ بنسبة ٢٥%، بينما كانت العينات المجمعة من المتطوعين الأصحاء سالبة للأجسام المضادة.

Introduction:

Hepatitis E is a common cause of acute hepatitis in areas with poor sanitation (1). Hepatitis E virus (HEV) is a spherical, non-enveloped with an icosahedral symmetry virus belongs to the Hepeviridae family. Viral particles are approximately 32 to 34 nm in diameter. HEV is a single-strand, positive-sense RNA virus with at least four known main genotypes of mammalian HEV and one avian HEV. HEV genotypes 1 and 2 are found exclusively in humans while genotypes 3 and 4 are found both in humans and other mammals (2- 4). Avian isolates of HEV are genetically distinct with a shorter (6.6 Kb) genome and only about 50% sequence homology with the mammalian isolates. The avian HEV constitute a fifth HEV genotype, these isolates are now considered as belonging to a separate genus (5).

Hepatitis E is transmitted by the fecal-oral route, usually via the consumption of contaminated water or food, human-to-human transmission of HEV is rare. Incubation time ranges from 2 weeks to 2 months with an average of 40 days. From a clinical point of view, hepatitis E is acute self-limiting and symptomatic disease that varies in severity from subclinical to fulminant. The mortality rate associated with HEV infection is 1 to 4% and can reach up to 20% during pregnancy ***(2, 3, 6)***. The acute hepatitis E virus has the highest attack rates in young adults and the disease is particularly severe among pregnant women. HEV superinfection can occur among persons with pre-existing chronic liver disease. In recent years, an increasing number of cases, mostly due to genotype 3 or 4 HEV, have been recognized (1, 7).

HEV is unique among the known hepatitis viruses, in which it has an animal reservoir. Domestic pigs and wild boars are the main animal reservoir for the genotypes 3 and 4 strains of HEV worldwide. Besides pigs, anti-HEV antibodies have also been detected

in many other animal species including deer, rats, dogs, cats, mongooses, cows, sheep, goats, avian species, rabbits and horses ***(8-11)***. Zoonotic transmission of hepatitis E raises an important public health concern over food safety and zoonotic risk. Several lines of evidence indicate that, in some cases involving HEV genotypes 3 and 4, animal to human transmissions occur. Individuals with direct contact with animals are at higher risk of HEV infection ***(8, 12, 13)***. Cross-species infections with HEV genotypes 3 and 4 have been demonstrated experimentally ***(14-16)***. Epidemics of hepatitis E have been reported primarily in developing regions of Africa, the Middle East, and Southeast and Central Asia; one epidemic occurred in North America (Mexico) ***(3, 15)***. Several studies have been done on HEV in different regions in Saudi Arabia such as Jeddah, Riyadh and Gizan ***(17-22)*** but no investigation has been done in Najran. Here, this study was carried out to evaluate anti-HEV seroprevalence in Najran Province.

Materials and methods:

A cross-sectional study was carried out to determine the seroprevalence of HEV infection in hepatic and non-hepatic persons in Najran. The individuals were informed in detail about the research and the protocol was approved by the Institutional Research Ethics Committee of Najran University.

Blood samples

Blood samples from a total of 1080 persons (844 male and 236 female), over the age of 20 years with a mean age of 38.4 years, were evaluated. Of these, 360 had chronic hepatitis and 720 were apparently healthy volunteer. The most common causes of chronic liver disease were hepatitis B virus (HBV) infection present in 58.3%, hepatitis C virus

(HCV) infection present in 33.4%, and HCV/HBV co-infection present in 8.3% of the persons Table 1.

Serological assays for anti-HEV IgG

All serum samples were tested for specific anti-HEV IgG antibodies by ELISA, according to the method described by the manufacturer, using commercially available reagents (HEV ELISA, DIAGNOSTIC AUTAMATION, INC, CA, USA). According to the manufacturer, this assay presents 99.8% sensitivity and 99.8% specificity. The results were scored as positive or negative according to standard procedures recommended by the manufacturers. The individuals were considered to be seropositive when they showed two repeated positive reactions. Positive and negative controls were included in all the ELISA microplates assayed.

Table 1. **Characteristics of 1080 persons evaluated in study**

Characteristic		**No.**	**(%)**
Gender	Male	844	78.9
	Female	236	21.1
Chronic liver disease	Yes	360	33.33
	No	720	66.66
Hepatitis infection	HCV	120	33.4
	HBV	210	58.3
	HBV/HCV	30	8.3

Statistical analysis

The statistical analysis was performed using the Chi-square (x2) test. The level of significance adopted for all tests was 5% ($p < 0.05$).

Results:

Seroprevalence of HEV in human samples

The results showed that anti-HEV IgG was detected in patients suffering from hepatitis only. No positive HEV samples were detected in apparently healthy volunteers. The overall anti-HEV IgG seroprevalence rate was 88 out of 1080 with percent of 8.1%. In 360 samples of hepatic patients, 88 developed HEV IgG. therefore, the prevalence of IgG HEV antibody in this group was 25%. Of these positive serum samples, 21 out of 30 from patients coinfected with HBV/HCV with percent of 66%, 30 out of 120 from patient infected with HCV with percent of 25% and 37 out of 210 from patient infected with hepatitis B with percent of 17.6%. There was no significant difference in HEV seropositivity between the subjects grouped according to gender or age ($p > 0.05$). However, the infection rate was always higher in male than female and the infection rate was higher in group aged from 30 to 40 years old than other two groups. The prevalence of HEV IgG seropositivity is showed in Tables 2 and 3.

Table 2. **Prevalence of hepatitis E virus IgG seropositivity**

Age (Year)	**Male** NO	%	**Female** NO	%	***P* value**
< 30	9/150	(6%)	2/48	(4.1 %)	> 0.05
30 - 39	38/388	(9.8%)	5/86	(7.3 %)	> 0.05
≥ 40	21/306	(6.9%)	5/102	(4.9 %)	> 0.05

Table 3. Relationship between hepatitis E virus infection and hepatitis B virus, hepatitis C virus or co-infection HBC/HCV

Characteristics	HEV positive IgG	Percentage	*P* value
HBV antibody positive	37/210	17.6%	> 0.05
HCV antibody positive	30/120	25%	> 0.05
HCV and HBV positive	21/30	66%	> 0.05

Discussion:

This study was carried out to determine the seroprevalence of HEV in Najran, and to evaluate whether the rate of seroprevalence of IgG anti-HEV antibodies is associated with sociodemographic variables and with seropositivity for hepatitis B, C virus infection. The region was chosen for the study because Najran is considered rural, based on sewage disposal and water sanitation systems in this area. Previous studies indicated that tests based upon open reading frame (ORF) 3 of HEV are of limited value for seroepidemiologic studies, whereas ORF2-based antigens have broad utility and yield data that are reproducible in more than one laboratory (23). So, ELISA method based on antigens derived from open reading frame (ORF2) was used in our study. The HEV overall seropositivity rate (8.1%) detected in Najran was lower than the average of other rural areas in Saudi Arabia as Gizan areas (14.9 %) and was similar to the mean rates of exposure HEV in urban area as Riyadh 9.1% (17- 20).

Our results showed that the infection rate was always higher in male than female and in patient's ages 30-40 years than other ages. Males are at higher risk of acquiring the infection than females and this is probably because of social habits rather than genetic factors. However, the difference in infection rate according to age or gender was insignificant. Our results were consistent with others (22) who mentioned that HEV seropositivity did not

significantly affected with age or gender. Our results were inconsistent with others who mentioned that HEV seropositivity was significantly affected with age or gender (9, 24, 25, 26). Significant association was observed between HEV seropositivity and HBV and HCV. It seems that HEV highly infect the patients infected with HBV, HCV or both viruses. However, the reasons for these results need to be investigated. Similar results were mentioned by others who mentioned that a significant association between anti-HEV and anti-HCV with donors who were positive to anti-HCV having about 5 times the risk of HEV than those who were anti-HCV negative (17).

Contact with animals and living in a rural habitat were the main risk factors for transmission of the disease (8, 12, 27). Detection of the virus in sheep, chicken or water samples which may refers to other possible sources of infection is needed. The contaminated water due to sewage system in Najran could be the possible source of infection (24).

Our study has limitations that should be noted. As is the case in many retrospective analyses, we were unable to collect all risk factors and characteristics of persons in the study. To our knowledge, the present study is the first seroepidemiological study on HEV infection in this unique population. The study showed that this virus is prevailed among the population and point out the need of further studies to define the clinical and epidemiological importance of HEV infection and to identify the risk factors involved in the epidemiology and pathogenesis of this infection.

References:

1.Aggarwal R and Naik S (2009): Epidemiology of hepatitis E: current status. J Gastroenterol Hepatol. 24 (9):1484-93.

2.Purcell RH (1996): Hepatitis E virus. In: Fields BN, Knipe DM, Howley PM, et al. editor. Fields Virology 3rd ed Vol 2. Philadelphia: Lippincott-Raven Publishers; p. 2831–2843.

3.Purcell RH and Emerson SU (2008). Hepatitis E: an emerging awareness of an old disease, J. Hepatol. 48:494–503.

4.Xing L, Kato K, Li T, Takeda N, Miyamura T, Hammar L and Cheng RH (1999): Recombinant hepatitis E capsid protein self-assembles into a dual-domain T = 1 particle presenting native virus epitopes, Virology 265:35–45.

5.Huang FF, Haqshenas G and Shivaprasad HL et al. (2002): Heterogeneity and seroprevalence of a newly identified avian hepatitis E virus from chickens in the United States. J. Clin. Microbiol. 40: 4197–4202.

6.Emerson SU and Purcell RH (2003): Hepatitis E virus, Rev. Med. Virol. 13:145–154.

7.Aggarwal R and Jameel S (2011): Hepatitis E. Hepatology. 54 (6):2218-26.

8.Meng XJ (2009): Hepatitis E virus: animal reservoirs and zoonotic risk, Vet. Microbiol. 140:256–265.

9.Pavio N, Meng XJ and Renou C (2010): Zoonotic hepatitis E: animal reservoirs and emerging risks. Vet Res. 41(6):46.

10.Reuter G, Fodor D, Forgach P, Katai A and Szucs G (2009): Characterization and zoonotic potential of endemic hepatitis E virus (HEV) strains in humans and animals in Hungary, J. Clin. Virol. 44: 277–281.

11.Saad MD, Hussein HA, Bashandy MM, Kamel HH, Earhart KC and Fryauff DJ et al., (2007): Hepatitis E virus infection in work horses in Egypt, Infect. Genet. Evol. 7:368–373

12.Favorov MO, Nazarova O and Margolis HS (1998): Is hepatitis E an emerging zoonotic disease? Am J Trop Med Hyg. 59: 242-246.

13.Tien NT, Clayson HT, Khiem HB, Sac PK, Corwin AL and Myint KS et al. (1997): Detection of immunoglobulin G to the hepatitis E virus among several animal species in Vietnam. Am J Trop Med Hyg. 57:211.

14. Goens SD and Perdue ML (2004): Hepatitis E viruses in humans and animals. Anim Health Res Rev. 5 (2):145-156.

15.Lu L, Li C and Hagedorn CH (2006): Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis, Rev. Med. Virol. 16:5–36.

16.Maneerat Y, Clayson ET, Myint KSA, Young GD and Innis BL (1996): Experimental infection of the laboratory rat with the hepatitis E virus. J Med Virol. 48:121–128.

17.Abdelaal M, Zawawi TH, Sobhi E, Jeje O, Gilpin C, Kinsara A, Osoba A and Oni GA (1998): Epidemiology of hepatitis E virus in male blood donors in Jeddah, Saudi Arabia. Ir J Med Sci. 167 (2):94-96.

18.Al-Knawy B, El-Mekki AA and Yarbough PO (1997): The role of hepatitis E virus

infection among patients with acute viral hepatitis in southern Saudi Arabia. Ann Saudi Med. 17 (1):32-34.

19.Arif M (1996): Enterically transmitted hepatitis in Saudi Arabia: an epidemiological study. Ann Trop Med Parasitol. 90 (2):197-201.

20.Arif M, Qattan I, Al-Faleh F and Ramia S (1994): Epidemiology of hepatitis E virus (HEV) infection in Saudi Arabia. Annals of Trop. Med and Parasitology; 88: 163-168.

21.Arif M, Qattan I and Ramia S (1996): Possible aetiological role of hepatitis E virus in acute non-A, non-B, non-C hepatitis in Saudi Arabia. Trans R Soc Trop Med Hyg. 90 (6):645-646.

22.Ayoola A, Aderoju A, Gadour MO, Al-Hazmi M, Hamza MK, Ene D, Hafeez M, Anderson D and Riddell M (2001): Serological profile of sporadic acute viral hepatitis in an area of hyper-endemic hepatitis B virus infection. Saudi J Gastroenterol. 7 (3):95-102.

23.Ghabrah TM, Tsarev S, Yarbough PO, Emerson SU, Strickland GT and Purcell RH (1998): Comparison of tests for antibody to hepatitis E virus. J Med Virol. 55 (2):134-137.

24.Cheng XF, Wen YF, Zhu M, Zhan SW, Zheng JX, Dong C, Xiang KX, Xia XB, Wang G and Han LF (2012): Serological and molecular study of hepatitis E virus among illegal blood donors. World J. Gastroenterol. 18 (9): 986–990.

25.Fix AD, Abdel-Hamid M, Purcell RH, Shehata MH, Abdel-Aziz F, Mikhail N, El Sebai H, Nafeh M, Habib M, Arthur RR, Emerson SU and Strickland GT (2000): Prevalence of antibodies to hepatitis E in two rural Egyptian communities. Am J Trop Med Hyg. 62 (4):519-23.

26.Houcine N, Jacques R, Salma F, Anne-Gaëlle D, Amin S, Mohsen H, Hamadi B, Christophe R, Patrice A, Mahjoub A and Caroline S (2012): Seroprevalence of hepatitis E virus infection in rural and urban populations, Tunisia. Clin Microbiol Infect.18 (5):119-121.

27.Eker A, Tansel O, Kunduracilar H, Tokuç B, Yuluğkural Z and Yüksel P (2009): Hepatitis E virus epidemiology in adult population in Edirne province, Turkey. Mikrobiyol Bul. 43 (2):251-258.